Table 9 CSF findings and attack severity in patients with acute disease in group I (i.e., ≤ 14 days since onset of the neurological symptoms)

WCC, all

Cells/µl

2 (0–651;71)

2 (0–373;15)

WCC, elevated

Samples

10/62 (16.1%)

1/7 (14.3%)

OCB, pattern 1

Samples

26/80 (32.5%)

13/20 (65%)

OCB, pattern 4

Samples

50/80 (62.5%)

4/20 (20%)

Link index

Samples

1/65 (1.5%)

0/14 (0%)

QIgG, all

Ratio

4.3 (1–22.4;66)

2.9 (1.6–7.5;14)

QIgG, elevated

Samples

1/66 (1.5%)

0/14 (0%)

QAlb, all

Ratio

9.3 (3.2–50.8;66)

6.9 (3.6–29.9;15)

QAlb, elevated

Samples

39/66 (59.1%)

7/15 (46.7%)

QAlb, if elevated

Ratio

12.5 (6.8–50.8;39)

9.8 (6.7–29.9;7)

CSF TP, all

Mg/dl

49 (18.2–240.4;63)

42.2 (17.5–175;13)

CSF TP, elevated

Samples

35/63 (55.6%)

6/13 (46.2%)

CSF TP, if elevated

Mg/dl

70.1 (45.3–240.4;35)

54.7 (48.6–175;6)

CSF TP, > 100 mg/dl

Samples

11/90 (12.2%)

1/18 (5.6%)

CSF L-lactate, all

Mmol/l

2.1 (1.3–4;60)

1.7 (1.3–3.5;13)

CSF L-lactate, elevated

Samples

16/60 (26.7%)

4/13 (30.8%)

CSF L-lactate, if elevated

Mmol/l

3.1 (2.2–4;16)

2.8 (2.6–3.5;4)

CSF L-lactate, > 3 mmol/l

Samples

11/85 (12.9%)

2/18 (11.1%)